Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNB-383B in Relapsed or Refractory Multiple Myeloma
NCT03933735Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of etentamig in multiple myeloma (MM), sponsored by AbbVie Inc.. Started Jun 2019; status: active, not recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03933735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933735.